GeNeuro Publishes Its 2020 Universal Registration Document
GENEVA–(BUSINESS WIRE)–Regulatory News:
GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, including multiple sclerosis, publishes its 2020 Universal Registration Document, in English, which has been filed on April 30, 2021 with the “Autorité des Marchés Financiers (AMF)”.
This document is available to the public free of charge, as provided for in applicable legislation, and may be viewed and downloaded on the Company’s website www.geneuro.com
The 2020 Universal Registration Document includes the annual financial report, the auditors’ reports and information about fees paid to statutory auditors, as well as the resolutions submitted to the Annual Shareholders’ Meeting of May 27, 2021.
About GeNeuro
GeNeuro‘s mission is to develop safe and effective treatments against neurological disorders and autoimmune diseases, such as multiple sclerosis, by neutralizing causal factors encoded by HERVs, which represent 8% of human DNA.
GeNeuro is based in Geneva, Switzerland and has R&D facilities in Lyon, France. It has rights to 17 patent families protecting its technology.
Contacts
GeNeuro
Jesús Martin-Garcia
Chairman and CEO
+41 22 552 4800
[email protected]
NewCap (France)
Louis-Victor Delouvrier /
Mathilde Bohin (investors)
+33 1 44 71 98 52
Arthur Rouillé (media)
+33 1 44 71 00 15
[email protected]
Halsin Partners
Mike Sinclair (media)
+44 20 7318 2955
[email protected]
LifeSci Advisors
Chris Maggos (investors)
+41 79 367 6254
[email protected]
